April 6, 2017
Zavante Therapeutics’ Zolyd met goal in a study for treating urinary tract infections
Zavante Therapeutics’ investigational product candidate, Zolyd (fosfomycin for injection, also known as ZTI-01), met the primary endpoint of statistical non-inferiority to piperacillin/tazobactam.